Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension

Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Böhm M

(2012), Hypertension, 60(2), 419-24

Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins

Liu S, Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H

(2012), Clin Exp Pharmacol Physiol, 39(8), 692-700

Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals

Li S, Roberts S, Plebanski M, Gouillou M, Spelman T, Latour P, Jackson D, Brown L, Sparrow RL, Prince HM, Hart D, Loveland BE, Gowans EJ

(2012), PLoS One, 7(8), e39368

High platelet reactivity and antiplatelet therapy resistance

Linden MD, Tran H, Woods R, Tonkin A

(2012), Semin Thromb Hemost, 38(2), 200-12

Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome

Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ, Krum H

(2012), Am J Physiol Heart Circ Physiol, 302(9), H1884-93

Cardiorenal syndrome: the emerging role of protein-bound uremic toxins

Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H

(2012), Circ Res, 111(11), 1470-83

Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate

Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, Kelly DJ, Krum H

(2012), PLoS One, 7(7), e41281

Health-related quality of life after renal denervation in patients with treatment-resistant hypertension

Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK, Shaw J, Krum H, Dixon JB, Barton DA, Schlaich MP

(2012), Hypertension, 60(6), 1479-84

A novel algorithm for individualized cardiac resynchronization therapy: rationale and design of the adaptive cardiac resynchronization therapy trial

Krum H, Lemke B, Birnie D, Lee KL, Aonuma K, Starling RC, Gasparini M, Gorcsan J, Rogers T, Sambelashvili A, Kalmes A, Martin D

(2012), Am Heart J, 163(5), 747-752.e1

Cardio-renal syndrome: new perspective in diagnostics

Iyngkaran P, Schneider H, Devarajan P, Anavekar N, Krum H, Ronco C

(2012), Semin Nephrol, 32(1), 3-17

The effects of terlipressin on regional hemodynamics and kidney function in experimental hyperdynamic sepsis

Ishikawa K, Wan L, Calzavacca P, Bellomo R, Bailey M, May CN

(2012), PLoS One, 7(2), e29693

Renal denervation in moderate to severe CKD

Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP

(2012), J Am Soc Nephrol, 23(7), 1250-7

Oblique axis body fracture--pitfalls in management

Goldschlager T, Leach JC, Williamson OD, Malham GM

(2012), Injury, 43(4), 505-8

The Australian approach to peri-operative fluid balance

Glassford NJ, Myles P, Bellomo R

(2012), Curr Opin Anaesthesiol, 25(1), 102-10

A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat

Gilbert RE, Zhang Y, Williams SJ, Zammit SC, Stapleton DI, Cox AJ, Krum H, Langham R, Kelly DJ

(2012), PLoS One, 7(10), e47160

Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial

Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA; Symplicity HTN-2 Investigators

(2012), Circulation, 126(25), 2976-82

Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β

Edgley AJ, Krum H, Kelly DJ

(2012), Cardiovasc Ther, 30(1), e30-40

Sustained activation of microglia in the hypothalamic PVN following myocardial infarction

Dworak M, Stebbing M, Kompa AR, Rana I, Krum H, Badoer E

(2012), Auton Neurosci, 169(2), 70-6

Transthoracic echocardiography findings - implications for clinical management

Coller J, Campbell D, Krum H, Prior D

(2012), Aust Fam Physician, 41(12), 954-8

Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention

Chan W, Stub D, Clark DJ, Ajani AE, Andrianopoulos N, Brennan AL, New G, Black A, Shaw JA, Reid CM, Dart AM, Duffy SJ; Melbourne Interventional Group Investigators

(2012), Am J Cardiol, 109(4), 478-85

459 460 461 462 463